201 related articles for article (PubMed ID: 17828283)
1. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
2. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
3. Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.
Ren J; Yu C; Wu S; Peng F; Jiang Q; Zhang X; Zhong G; Shi H; Chen X; Su X; Luo X; Zhu W; Wei Y
Curr Cancer Drug Targets; 2014; 14(2):167-80. PubMed ID: 24410728
[TBL] [Abstract][Full Text] [Related]
4. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells.
Ueda K; Kawashima H; Ohtani S; Deng WG; Ravoori M; Bankson J; Gao B; Girard L; Minna JD; Roth JA; Kundra V; Ji L
Cancer Res; 2006 Oct; 66(19):9682-90. PubMed ID: 17018626
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy.
Ohtani S; Iwamaru A; Deng W; Ueda K; Wu G; Jayachandran G; Kondo S; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jul; 67(13):6293-303. PubMed ID: 17616688
[TBL] [Abstract][Full Text] [Related]
6. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
[TBL] [Abstract][Full Text] [Related]
8. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.
Ito I; Ji L; Tanaka F; Saito Y; Gopalan B; Branch CD; Xu K; Atkinson EN; Bekele BN; Stephens LC; Minna JD; Roth JA; Ramesh R
Cancer Gene Ther; 2004 Nov; 11(11):733-9. PubMed ID: 15486560
[TBL] [Abstract][Full Text] [Related]
9. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo.
Ji L; Nishizaki M; Gao B; Burbee D; Kondo M; Kamibayashi C; Xu K; Yen N; Atkinson EN; Fang B; Lerman MI; Roth JA; Minna JD
Cancer Res; 2002 May; 62(9):2715-20. PubMed ID: 11980673
[TBL] [Abstract][Full Text] [Related]
10. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy.
Ling C; Xie Y; Zhao D; Zhu Y; Xiang J; Yang J
Cancer Gene Ther; 2012 Oct; 19(10):697-706. PubMed ID: 22863759
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1.
Liu Q; Zhao XY; Bai RZ; Liang SF; Nie CL; Yuan Z; Wang CT; Wu Y; Chen LJ; Wei YQ
Oncol Rep; 2009 Nov; 22(5):1069-75. PubMed ID: 19787223
[TBL] [Abstract][Full Text] [Related]
12. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R
Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070
[TBL] [Abstract][Full Text] [Related]
14. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
17. Enhanced induction of Bax gene expression in H460 and H1299 cells with the combined treatment of cisplatin and adenovirus mediated wt-p53 gene transfer.
Choi JH; Ahn KS; Kim J; Hong YS
Exp Mol Med; 2000 Mar; 32(1):23-8. PubMed ID: 10762058
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.
Li D; Zhang Y; Xie Y; Xiang J; Zhu Y; Yang J
Cancer Gene Ther; 2013 Apr; 20(4):251-9. PubMed ID: 23470565
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo.
Li L; Yu C; Ren J; Ye S; Ou W; Wang Y; Yang W; Zhong G; Chen X; Shi H; Su X; Chen L; Zhu W
J Cancer Res Clin Oncol; 2014 Jun; 140(6):895-907. PubMed ID: 24659339
[TBL] [Abstract][Full Text] [Related]
20. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
